TXG

PLEASANTON, Calif., July 15, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced it will report financial results for the second quarter ended June 30, 2026 after market close on Thursday, August 6, 2026. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call. Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 45 days after the event. About 10x Genomics 10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube. Disclosure Information 10x Genomics uses filings with the Securities and Exchange Commission, its website (https://www.10xgenomics.com/), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Contacts Investors: [email protected] Media: [email protected] View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-to-report-second-quarter-2026-financial-results-on-august-6-2026-302826655.html

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. 10x Genomics (TXG) has been drawing fresh attention after quarterly results topped analyst revenue and EPS forecasts, even as the company was removed from several Russell value benchmarks in late June. For you as an investor, that mix of index-related technical pressure and better than expected fundamentals creates an interesting setup to reassess what is actually driving 10x Genomics stock right now. See our latest analysis for 10x Genomics. Since earnings, 10x Genomics has seen a 30 day share price return of 28.41% and a 90 day share price return of 62.91%, while the 1 year total shareholder return of 209.67% contrasts with a 3 year total shareholder return that is down 37.07% and a 5 year total shareholder return that is down 77.83%. This pattern suggests strong recent momentum following earlier weakness. If you are watching how sentiment in genomics and related tools is shifting, it can be useful to compare 10x Genomics with other companies benefiting from AI linked themes using the 40 healthcare AI stocks 10x Genomics just delivered better than expected numbers and a sharp share price move, yet it still sits on mixed longer term returns and an annual loss. Is this a strong business now priced too richly, or not richly enough? The most followed 10x Genomics narrative puts fair value at $20.14 using a 7.84% discount rate, compared with the latest close of $37.47. This frames today’s price as demanding. Read the complete narrative. Want to see what has to happen for that gap to close? The narrative leans on steady revenue gains, margin repair, and a punchy future earnings multiple. The exact mix of growth, profitability and share count assumptions may surprise you. Result: Fair Value of $20.14 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the 10x Genomics story still hinges on sensitive academic funding trends and pressure on instrument pricing, both of which could quickly challenge today’s positive assumptions. Find out about the key risks to this 10x Genomics narrative. Given the mix of cautious and optimistic views around 10x Genomics, it is worth acting now to review the underlying data and decide what matters most to you, then weigh the 1 key reward and 2 important warning signs hig...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at 10x Genomics (NASDAQ:TXG) and the best and worst performers in the life sciences tools & services industry. The life sciences tools and services sector supports biotech and pharmaceutical R&D and commercialization by providing lab equipment, data analytics, and clinical trial services. These companies benefit from recurring revenue and high margins on specialized products. Looking ahead, the sector is supported by tailwinds like advancements in genomics, personalized medicine, and the use of AI in drug discovery. However, the persistent challenge is dependence on the R&D budgets of large pharmaceutical companies and the volatility of smaller biotech firms. Future headwinds include uncertain research funding and pricing pressures from cost-conscious customers. The 21 life sciences tools & services stocks we track reported a satisfactory Q1. As a group, revenues beat analysts’ consensus estimates by 1.1% while next quarter’s revenue guidance was 2.1% above. Luckily, life sciences tools & services stocks have performed well with share prices up 23.8% on average since the latest earnings results. Founded in 2012 by scientists seeking to overcome limitations in traditional biological research methods, 10x Genomics (NASDAQ:TXG) develops instruments, consumables, and software that enable researchers to analyze biological systems at single-cell resolution and spatial context. 10x Genomics reported revenues of $150.8 million, down 2.6% year on year. This print exceeded analysts’ expectations by 2.9%. Overall, it was a very strong quarter for the company with a beat of analysts’ EPS estimates. 10x Genomics delivered the slowest revenue growth of the whole group. Interestingly, the stock is up 69.5% since reporting and currently trades at $38. Is now the time to buy 10x Genomics? Access our full analysis of the earnings results here, it’s free. Founded in 1923 and serving as a critical link in the pharmaceutical supply chain, West Pharmaceutical Services (NYSE:WST) manufactures specialized packaging, containment systems, and delivery devices for injectable drugs and healthcare products. West Pharmaceutical Services reported revenues of $844.9 million, up 21% year on year, outperforming analysts’ expectations by 8.4...

The past six months have been a windfall for 10x Genomics’s shareholders. The company’s stock price has jumped 116%, setting a new 52-week high of $34.69 per share. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation. Is now the time to buy 10x Genomics, or should you be careful about including it in your portfolio? Get the full breakdown from our expert analysts, it’s free. Despite the momentum, we’re swiping left on 10x Genomics for now. Here are three reasons why TXG doesn’t excite us, plus one stock we’d rather own. We at StockStory place the most emphasis on long-term growth, but within healthcare, a stretched historical view may miss recent innovations or disruptive industry trends. 10x Genomics’s recent performance shows its demand has slowed as its annualized revenue growth of 1.1% over the last two years was below its five-year trend. We’re wary when companies in the sector see decelerations in revenue growth, as it could signal changing consumer tastes aided by low switching costs. Larger companies benefit from economies of scale, where fixed costs like infrastructure, technology, and administration are spread over a higher volume of goods or services, reducing the cost per unit. Scale can also lead to bargaining power with suppliers, greater brand recognition, and more investment firepower. A virtuous cycle can ensue if a scaled company plays its cards right. With just $638.8 million in revenue over the past 12 months, 10x Genomics is a small company in an industry where scale matters. This makes it difficult to build trust with customers because healthcare is heavily regulated, complex, and resource-intensive. Growth gives us insight into a company’s long-term potential, but how capital-efficient was that growth? A company’s ROIC explains this by showing how much operating profit it makes compared to the money it has raised (debt and equity). 10x Genomics’s five-year average ROIC was negative 44.3%, meaning management lost money while trying to expand the business. Its returns were among the worst in the healthcare sector. 10x Genomics doesn’t pass our quality test. Following the recent surge, the stock trades at $34.69 per share (or a forward price-to-sales ratio of 6.6×). The market typically values companies like 10x Genomics based on their anticipated profits fo...

10x Genomics' first quarter results were met with a negative market reaction, despite exceeding Wall Street’s revenue and earnings expectations. Management credited continued momentum in single cell and spatial consumable volumes, particularly from newer product lines like FLEX Apex and Xenium. CEO Serge Saxonov emphasized that the recent Atara launch was a pivotal development, describing it as a response to longstanding customer demands for scalable, high-resolution spatial biology tools. The company noted that, while the macro environment for capital equipment remains constrained, preorders and customer interest for Atara were strong, even as some customers delayed purchases of existing spatial instruments in anticipation of the new platform’s arrival. Is now the time to buy TXG? Find out in our full research report (it’s free). Revenue: $150.8 million vs analyst estimates of $146.6 million (2.6% year-on-year decline, 2.9% beat) Adjusted EPS: $0.07 vs analyst estimates of -$0.06 (significant beat) Adjusted EBITDA: $15.25 million The company reconfirmed its revenue guidance for the full year of $612.5 million at the midpoint Operating Margin: -11.3%, up from -25.4% in the same quarter last year Market Capitalization: $2.67 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Patrick Donnelly (Citi): Asked about Atara’s early demand signals and how launch timing is impacting the broader portfolio. CEO Serge Saxonov said demand is “really strong,” with broad interest across customer types, and acknowledged that customers are delaying some spatial purchases but these effects are built into guidance. Matthew Larew (William Blair): Inquired about the scale and timeline of AI-driven demand. Saxonov responded that AI is now a pervasive driver across customer projects, fueling demand for 10x Genomics’ data-generation platforms and suggesting the total addressable market may expand significantly. Madeline Mollman (Wolfe Research): Questioned potential margin impacts from Atara and inflationary costs. CFO Adam Taich indicated margins may see slight pressure as Atara launches, but expects to maintain mid-60% gross margins...

Interested in 10x Genomics? Here are five stocks we like better. 10x Genomics said Q1 revenue rose 9% year over year excluding prior-year settlement revenue, with strength in consumables offsetting a decline in instrument sales. Total revenue was $150.8 million, while consumables grew 13% and spatial consumables jumped 31%. The company’s main focus was the launch of Atera, a new spatial biology platform management called its most important product introduction ever. Initial shipments are expected in the second half of 2026, and management said early customer interest has been stronger than expected. Despite expected near-term pressure from customers waiting for Atera, 10x Genomics kept full-year 2026 revenue guidance at $600 million to $625 million. Management still expects double-digit growth in both single-cell consumables reactions and spatial consumables revenue, and sees AI-driven research and translational studies as long-term growth drivers. Strategic Buy Lights Up This Biotech Stock: Time to Invest? 10x Genomics (NASDAQ:TXG) reported a first-quarter revenue increase excluding prior-year settlement revenue and used its earnings call to emphasize the launch of Atera, a new spatial biology instrument platform that management described as the most significant product introduction in the company’s history. Chief Executive Officer and Co-Founder Serge Saxonov said the company had a “really nice start to the year,” citing sales momentum, product launches and execution. Revenue for the quarter ended March 31, 2026, was $150.8 million, up 9% year over year when excluding non-recurring settlement revenue in the first quarter of 2025. → Insider Sales: Top AST SpaceMobile Insider Cuts Postion Over 30% Chief Financial Officer Adam Taich said the quarter reflected continued growth in consumables, including both single-cell and spatial products, as well as some benefit from orders received late in the fourth quarter of 2025 that shipped in early January. Total consumables revenue rose 13% year over year, according to Taich. Single-cell consumables revenue increased 6%, supported by double-digit growth in reaction volumes. Taich said Flex continued to be the company’s most popular assay by volume during the quarter. → Light Speed Returns: Corning Cashes In on NVIDIA Growth Spatial consumables revenue grew 31%, driven by Xenium consumables. Saxonov said spatial biolo...

Image source: The Motley Fool. Thursday, May 7, 2026 at 4:30 p.m. ET Chief Executive Officer and Co-Founder — Serge Saxonov Chief Financial Officer — Adam Taich Senior Director, Investor Relations and Strategic Finance — Cassie Corneau we will conduct a question and answer session. To ask a question at this time, you will need to press star. As a reminder, this conference call is being recorded. I would now like to turn the call over to Cassie Corneau, Senior Director, Investor Relations and Strategic Finance. Thank you. Please go ahead. Cassie Corneau: Thank you, and good afternoon, everyone. Earlier today, 10x Genomics, Inc. released financial results for the first quarter ended 03/31/2026. If you have not received this news release or would like to be added to the company's distribution list, please send an email to [email protected]. An archived webcast of this call will be available on the company's website at 10xgenomics.com for at least 45 days following this call. Before we begin, I would like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements. Additional information regarding these risks, uncertainties, and factors that could cause results to differ appears in the press release 10x Genomics, Inc. issued today and in the documents and reports filed by 10x Genomics, Inc. from time to time with the Securities and Exchange Commission. 10x Genomics, Inc. disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. Joining the call today are Serge Saxonov, our CEO and Co-Founder, and Adam Taich, our Chief Financial Officer. We will host a question and answer session after our prepared remarks. We ask analysts to please keep to one question so that we may accommodate everyone in queue. With that, I will now turn the call over to Serge. Serge Saxonov: Thanks, Cassie, and good afternoon, everyone. What a really nice start to the year, with solid sales momentum, a step-change advance in our product roadmap, and strong executi...

10x Genomics TXG delivered a loss per share of 10 cents in first-quarter 2026, narrower than the year-earlier loss per share of 36 cents. The figure surpassed the Zacks Consensus Estimate by 65.5%. TXG registered revenues of $150.8 million in the first quarter of 2026, which decreased about 2.6% year over year. Excluding $16.8 million related to one-time license and royalty revenue in the first quarter of 2025, revenues increased 9% year over year. However, the figure surpassed the Zacks Consensus Estimate by 3.57%. The company reports revenue under two primary segments: Products and Services and License and royalty revenue. Products and Services revenue totaled $149.9 million, up approximately 8.8% year over year. Within this segment, Total instruments revenues totaled $11.3 million, down 23.9% year over year. In contrast, Total consumables revenues were $129.8 million, representing a 12.5% year-over-year increase. Services revenue totaled $8.8 million, up 15.4% year over year. Meanwhile, License and royalty revenue was $0.9 million compared with $17.1 million in the prior-year quarter, which included $16.8 million related to one-time license and royalty revenue. Geographically, 10x Genomics derives revenues from three major regions: the Americas, Europe, the Middle East and Africa (EMEA), and Asia-Pacific. In the first quarter of 2026, Total Americas’ revenues were $80.1 million, reflecting a 11.6% year-over-year decline. EMEA revenues totaled $36.9 million, up approximately 15.5% year over year. Meanwhile, Total Asia-Pacific revenues were $33.9 million, representing 4.4% year-over-year growth. 10x Genomics price-consensus-eps-surprise-chart | 10x Genomics Quote In the quarter under review, TXG’s gross profit improved 0.7% year over year to $106.2 million. The gross margin expanded 220 basis points (bps) to 70.3%. Selling, general and administrative expenses fell 26% year over year to $66.4 million. Research and development expenses declined 11.5% year over year to $56.8 million. Total operating expenses of $123.2 million decreased 14.9% year over year. Total operating loss was $17 million, reflecting an improvement from the prior-year loss of $39.3 million. TXG exited the first quarter of 2026 with cash, cash equivalents and marketable securities of $539.8 million, up from $523.4 million at the end of the fourth quarter of 2025. Importantly, the company e...

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Revenue growth of 9% (excluding prior-year settlements) was driven by double-digit volume increases in single cell consumables and strong Xenium momentum in spatial biology. The launch of Atara represents the most significant product introduction in company history, designed to eliminate historical trade-offs between throughput, sensitivity, and scale. Management attributes single cell success to the FLEX and FLEX Apex products, which have unlocked new demand waves through more accessible pricing structures. The strategic focus has shifted toward enabling 'biology at scale,' moving from fragmented toolsets to integrated spatial analysis of molecules, cells, and tissues simultaneously. AI is identified as a structural tailwind, with management positioning their platforms as the essential data engines for building large-scale virtual models of biology. Operational discipline led to a $113 million year-over-year increase in cash reserves despite a challenging capital equipment environment and macro uncertainties. The company is increasingly targeting translational research and diagnostics, focusing on identifying drug targets and biomarkers in large clinical cohorts. Full-year 2026 revenue guidance of $600 million to $625 million assumes double-digit growth in single cell reaction volumes and spatial consumables. Management anticipates a sequential revenue step-down in Q2 and Q3 as customers delay current spatial purchases in anticipation of Atara shipments. Atara shipments are expected to begin contributing meaningfully in Q4 2026, though initial production capacity will be limited during the ramp-up phase. Gross margins are projected to remain in the mid-60s for the full year, with some anticipated pressure in Q4 due to the lower-margin profile of new instrument launches. The 2027 outlook is framed as the 'Year of Atara,' expecting stabilized single cell pricing and exponential growth in AI-driven research demand. Operating expenses decreased 20% (excluding settlement gains) due to disciplined cost management, lower legal fees, and reduced personnel costs. Management acknowledged a 'market freezing' effect where customers are pausing Xenium purchases to evaluate the Atara platform. The company is monitoring i...

PLEASANTON, Calif. (AP) — PLEASANTON, Calif. (AP) — 10x Genomics Inc. (TXG) on Thursday reported a loss of $13.5 million in its first quarter. The Pleasanton, California-based company said it had a loss of 10 cents per share. The results beat Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 29 cents per share. The life science technology company posted revenue of $150.8 million in the period, which also topped Street forecasts. Eight analysts surveyed by Zacks expected $145.6 million. 10x Genomics expects full-year revenue in the range of $600 million to $625 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on TXG at https://www.zacks.com/ap/TXG

PLEASANTON, Calif., May 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2026. Recent Updates Revenue was $150.8 million for the first quarter of 2026, representing a 3% decrease over the corresponding period of 2025. Excluding $16.8 million related to one-time license and royalty revenue in the first quarter of 2025, revenue increased 9% over the corresponding period of 2025. Launched Atera, a new platform to redefine how biology is measured and understood. Atera was engineered to deliver spatial whole-transcriptome analysis with single-cell sensitivity at unprecedented scale. The Company expects to start shipping Atera in the second half of 2026. Announced a partnership with Bioptimus, a global AI biotech company, to launch STELA, a multinational spatial data generation initiative to create foundational datasets connecting underlying biology with disease outcomes. The initiative is starting this effort on our Xenium platform and plans to expand to Atera over time. Ended the first quarter of 2026 with cash and cash equivalents and marketable securities of $539.8 million, representing a $112.9 million increase from March 31, 2025. "We had a solid start to the year, with double-digit growth in Single Cell consumables reaction volumes and double-digit growth in Spatial consumables revenue," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "The biggest highlight is our recent launch of Atera, which represents the most significant product introduction in our history. We are extremely encouraged by the extraordinary early customer response." First Quarter 2026 Financial Results Revenue was $150.8 million for the first quarter of 2026, a 3% decrease from the corresponding period of 2025. Excluding $16.8 million related to a patent litigation settlement recognized in the first quarter of 2025, revenue increased 9% over the corresponding period of 2025. Gross margin was 70% for the first quarter of 2026, as compared to 68% for the corresponding prior year period. The increase in gross margin was primarily due to lower warranty costs and lower inventory write-downs, partially offset by a decrease in license and royalty revenue reflecting a non-recurring royalty benefit recognized in the first quarter of 2025. Operating expenses were $123...

For the quarter ended March 2026, 10x Genomics (TXG) reported revenue of $150.84 million, down 2.6% over the same period last year. EPS came in at -$0.10, compared to -$0.36 in the year-ago quarter. The reported revenue represents a surprise of +3.57% over the Zacks Consensus Estimate of $145.65 million. With the consensus EPS estimate being -$0.29, the EPS surprise was +65.52%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how 10x Genomics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Services: $8.83 million versus the four-analyst average estimate of $8.05 million. The reported number represents a year-over-year change of +15.4%. Revenues- Instruments: $11.26 million versus the three-analyst average estimate of $12.47 million. The reported number represents a year-over-year change of -24%. Revenues- Instruments- Single Cell: $5.22 million versus $4.55 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -11.7% change. Revenues- Consumables- Single Cell: $88.89 million versus $87.8 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +5.7% change. Revenues- Consumables- Spatial: $40.91 million versus the three-analyst average estimate of $36.76 million. The reported number represents a year-over-year change of +30.9%. Revenues- Consumables: $129.8 million versus the three-analyst average estimate of $124.56 million. The reported number represents a year-over-year change of +12.5%. Revenues- Instruments- Spatial: $6.04 million compared to the $7.96 million average estimate based on three analysts. The reported number represents a change of -32.2% year over year. View all Key Company Metrics for 10x Genomics here>>> Shares of 10x Genomics have returned -1.2% over the past month versus the Zacks S&P 500 composite's +11.4% change. The stock currently...